Top-Rated StocksTop-RatedNASDAQ:PCRX Pacira BioSciences (PCRX) Stock Price, News & Analysis → Trump just won 2024 (From Porter & Company) (Ad) Free PCRX Stock Alerts $26.95 +0.70 (+2.67%) (As of 05:12 PM ET) Add Compare Share Share Today's Range$26.27▼$27.1250-Day Range$25.50▼$31.4152-Week Range$25.33▼$47.01Volume449,862 shsAverage Volume489,742 shsMarket Capitalization$1.25 billionP/E Ratio33.27Dividend YieldN/APrice Target$49.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Pacira BioSciences alerts: Email Address Pacira BioSciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside83.7% Upside$49.50 Price TargetShort InterestHealthy7.42% of Shares Sold ShortDividend StrengthN/ASustainability-1.89Upright™ Environmental ScoreNews Sentiment0.47Based on 8 Articles This WeekInsider TradingSelling Shares$2.79 M Sold Last QuarterProj. Earnings Growth29.82%From $2.18 to $2.83 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.97 out of 5 starsMedical Sector10th out of 927 stocksPharmaceutical Preparations Industry3rd out of 420 stocks 4.5 Analyst's Opinion Consensus RatingPacira BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePacira BioSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.42% of the outstanding shares of Pacira BioSciences have been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Pacira BioSciences has recently decreased by 7.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePacira BioSciences has received a 52.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Bupivacaine", "Cryotherapy devices", and "Drug delivery devices" products. See details.Environmental SustainabilityThe Environmental Impact score for Pacira BioSciences is -1.89. Previous Next 3.0 News and Social Media Coverage News SentimentPacira BioSciences has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Pacira BioSciences this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for PCRX on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat Follows6 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,785,628.00 in company stock.Percentage Held by InsidersOnly 6.60% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Pacira BioSciences are expected to grow by 29.82% in the coming year, from $2.18 to $2.83 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 33.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.16.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 33.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 214.44.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Pacira BioSciences Stock (NASDAQ:PCRX)Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.Read More PCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCRX Stock News HeadlinesApril 30, 2024 | globenewswire.comPacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024April 29, 2024 | americanbankingnews.comQ2 2025 Earnings Estimate for Pacira BioSciences, Inc. Issued By Zacks Research (NASDAQ:PCRX)May 1, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 17, 2024 | nasdaq.comOversold Conditions For Pacira BioSciences (PCRX)April 11, 2024 | finance.yahoo.comPacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trendApril 9, 2024 | markets.businessinsider.comUnderstanding Key Factors Behind Pacira Pharmaceuticals’ Analyst RatingApril 6, 2024 | nasdaq.comCommit To Purchase Pacira BioSciences At $15, Earn 12.5% Annualized Using OptionsApril 2, 2024 | globenewswire.comPacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMay 1, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.March 16, 2024 | finance.yahoo.comPCRX Apr 2024 22.500 putMarch 13, 2024 | marketwatch.comPacira's PCRX-201 Gets FDA RMAT Designation in Knee OsteoarthritisMarch 13, 2024 | markets.businessinsider.comPacira BioSciences Receives RMAT Designation For Gene Therapy Product Candidate In OsteoarthritisMarch 13, 2024 | globenewswire.comPacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the KneeMarch 9, 2024 | finance.yahoo.comDirector Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX)March 6, 2024 | globenewswire.comPacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare ConferenceMarch 4, 2024 | markets.businessinsider.comBuy Rating for Pacira Pharmaceuticals Amid Strong Growth Prospects and Robust IP ProtectionMarch 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pacira Pharmaceuticals Amid Strategic Growth Initiatives and Management RestructuringMarch 1, 2024 | markets.businessinsider.comNavigating 4 Analyst Ratings For Pacira BioSciencesMarch 1, 2024 | finance.yahoo.comPacira BioSciences Full Year 2023 Earnings: EPS Beats ExpectationsMarch 1, 2024 | finance.yahoo.comPacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | markets.businessinsider.comStrong Buy Rating for Pacira Pharmaceuticals Amid Favorable NOPAIN Act Implications and Strategic Growth InitiativesMarch 1, 2024 | finance.yahoo.comQ4 2023 Pacira Biosciences Inc Earnings CallFebruary 29, 2024 | msn.comPacira BioSciences GAAP EPS of $0.54 beats by $0.15, revenue of $181.2M beats by $0.34MFebruary 29, 2024 | finance.yahoo.comPacira BioSciences Inc (PCRX) Reports Record Revenues and Robust Earnings for Full-Year 2023February 29, 2024 | globenewswire.comPacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 28, 2024 | benzinga.comPreview: Pacira BioSciences's EarningsFebruary 28, 2024 | msn.comPacira BioSciences Q4 2023 Earnings PreviewSee More Headlines Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/01/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PCRX CUSIP69512710 CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees711Year FoundedN/APrice Target and Rating Average Stock Price Target$49.50 High Stock Price Target$57.00 Low Stock Price Target$42.00 Potential Upside/Downside+88.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.81 Trailing P/E Ratio32.41 Forward P/E Ratio12.04 P/E GrowthN/ANet Income$41.96 million Net Margins6.22% Pretax Margin9.14% Return on Equity12.81% Return on Assets6.80% Debt Debt-to-Equity Ratio0.59 Current Ratio5.24 Quick Ratio4.17 Sales & Book Value Annual Sales$674.98 million Price / Sales1.81 Cash Flow$3.99 per share Price / Cash Flow6.58 Book Value$18.74 per share Price / Book1.40Miscellaneous Outstanding Shares46,520,000Free Float43,452,000Market Cap$1.22 billion OptionableOptionable Beta0.76 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Charles A. Reinhart III (Age 63)C.P.A., M.B.A., Chief Financial Officer Comp: $780.58kMr. Daryl Gaugler (Age 62)Chief Operating Officer Comp: $778.77kMs. Kristen Williams J.D. (Age 50)Chief Administrative Officer & Secretary Comp: $799.63kMr. Anthony Molloy III (Age 50)Esq., Chief Legal & Compliance Officer Comp: $581.41kMr. David M. Stack (Age 74)Advisor Comp: $1.54MMr. Frank D. Lee (Age 56)CEO & Director Ms. Lauren Bullaro Riker (Age 45)Principal Accounting Officer & Senior VP of Finance Comp: $288.81kSusan MescoHead of Investor RelationsMr. Richard KahrVice President of Human ResourcesDr. Jonathan Slonin M.D. (Age 49)Chief Medical Officer Comp: $815.25kMore ExecutivesKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNAgios PharmaceuticalsNASDAQ:AGIOADC TherapeuticsNYSE:ADCTAtea PharmaceuticalsNASDAQ:AVIRNektar TherapeuticsNASDAQ:NKTRView All CompetitorsInsiders & InstitutionsBaillie Gifford & Co.Sold 62,492 shares on 5/1/2024Ownership: 2.151%Mirae Asset Global Investments Co. Ltd.Sold 896 shares on 5/1/2024Ownership: 0.045%Smith Group Asset Management LLCBought 7,209 shares on 5/1/2024Ownership: 0.015%Allspring Global Investments Holdings LLCBought 5,433 shares on 4/30/2024Ownership: 0.022%Principal Financial Group Inc.Bought 2,553 shares on 4/29/2024Ownership: 0.571%View All Insider TransactionsView All Institutional Transactions PCRX Stock Analysis - Frequently Asked Questions Should I buy or sell Pacira BioSciences stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCRX shares. View PCRX analyst ratings or view top-rated stocks. What is Pacira BioSciences' stock price target for 2024? 10 brokerages have issued 1-year price objectives for Pacira BioSciences' shares. Their PCRX share price targets range from $42.00 to $57.00. On average, they expect the company's stock price to reach $49.50 in the next twelve months. This suggests a possible upside of 83.7% from the stock's current price. View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts. How have PCRX shares performed in 2024? Pacira BioSciences' stock was trading at $33.74 at the start of the year. Since then, PCRX stock has decreased by 20.1% and is now trading at $26.95. View the best growth stocks for 2024 here. When is Pacira BioSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our PCRX earnings forecast. How can I listen to Pacira BioSciences' earnings call? Pacira BioSciences will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) issued its quarterly earnings results on Thursday, February, 29th. The company reported $0.71 EPS for the quarter, meeting analysts' consensus estimates of $0.71. The company had revenue of $181.24 million for the quarter, compared to the consensus estimate of $180.60 million. Pacira BioSciences had a net margin of 6.22% and a trailing twelve-month return on equity of 12.81%. What ETFs hold Pacira BioSciences' stock? ETFs with the largest weight of Pacira BioSciences (NASDAQ:PCRX) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Pacira BioSciences issued on next quarter's earnings? Pacira BioSciences updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $680.0 million-$705.0 million, compared to the consensus revenue estimate of $722.5 million. What is Dave Stack's approval rating as Pacira BioSciences' CEO? 54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA). Who are Pacira BioSciences' major shareholders? Pacira BioSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (2.24%), Baillie Gifford & Co. (2.15%), Principal Financial Group Inc. (0.57%), Tributary Capital Management LLC (0.54%), Assenagon Asset Management S.A. (0.42%) and Gradient Investments LLC (0.30%). Insiders that own company stock include Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston. View institutional ownership trends. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PCRX) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlace😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
